Trial Profile
Immunotherapy by Nivolumab in Neoadjuvant and Adjuvant Setting in Patients With Advanced HCC Treated by Electroporation in Curative Intent: French Multicenter Phase 2 Therapeutic Trial.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms NIVOLEP
- 17 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 19 Jul 2021 Planned End Date changed from 30 Sep 2020 to 30 Nov 2023.
- 19 Jul 2021 Planned primary completion date changed from 30 Sep 2020 to 11 Nov 2023.